Journal Citations
References for Cell Lines in the Open Distribution List
Click on a topic to view the section, or click here to show all the sections at once.
Master List of all References for Repository
- 1. C. P. Anderson, C. P. Reynolds, Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant. 2002;30:135-140.
- 2. C. P. Anderson, R. C. Seeger, N. Satake, H. L. Monforte-Munoz, N. Keshelava, H. H. Bailey, C. P. Reynolds, Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol. 2001;23:500-505.
- 3. C. P. Anderson, J. M. Tsai, W. E. Meek, R. M. Liu, Y. Tang, H. J. Forman, C. P. Reynolds, Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res. 1999;246:183-192.
- 4. E. F. Attiyeh, J. M. Maris, R. Lock, C. P. Reynolds, M. H. Kang, H. Carol, R. Gorlick, E. A. Kolb, S. T. Keir, J. Wu, Y. Landesman, S. Shacham, D. Lyalin, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer. 2016;63:276-286.
- 5. V. Batra, J. M. Maris, M. H. Kang, C. P. Reynolds, P. J. Houghton, D. Alexander, E. A. Kolb, R. Gorlick, S. T. Keir, H. Carol, R. Lock, C. A. Billups, M. A. Smith, Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59:749-752.
- 6. W. Cai, N. V. Maldonado, W. Cui, N. Harutyunyan, L. Ji, R. Sposto, C. P. Reynolds, N. Keshelava, Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer. 2010;103:1369-1379.
- 7. H. Carol, I. Boehm, C. P. Reynolds, M. H. Kang, J. M. Maris, C. L. Morton, R. Gorlick, E. A. Kolb, S. T. Keir, J. Wu, A. E. Wozniak, Y. Yang, M. Manfredi, J. Ecsedy, J. Wang, G. Neale, P. J. Houghton, M. A. Smith, R. B. Lock, Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 2011;68:1291-1304.
- 8. H. Carol, R. Gorlick, E. A. Kolb, C. L. Morton, D. M. Manesh, S. T. Keir, C. P. Reynolds, M. H. Kang, J. M. Maris, A. Wozniak, I. Hickson, D. Lyalin, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, R. Lock, Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2014;61:245-252.
- 9. H. Carol, P. J. Houghton, C. L. Morton, E. A. Kolb, R. Gorlick, C. P. Reynolds, M. H. Kang, J. M. Maris, S. T. Keir, A. Watkins, M. A. Smith, R. B. Lock, Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;54:707-715.
- 10. H. Carol, R. Lock, P. J. Houghton, C. L. Morton, E. A. Kolb, R. Gorlick, C. P. Reynolds, J. M. Maris, S. T. Keir, C. A. Billups, M. A. Smith,
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2009;53:1255-1263.
- 11. H. Carol, J. M. Maris, M. H. Kang, C. P. Reynolds, E. A. Kolb, R. Gorlick, S. T. Keir, J. Wu, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, R. B. Lock, D. Lyalin,
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2014;61:1493-1496.
- 12. H. Carol, C. L. Morton, R. Gorlick, E. A. Kolb, S. T. Keir, C. P. Reynolds, M. H. Kang, J. M. Maris, C. Billups, M. A. Smith, P. J. Houghton, R. B. Lock, Initial testing
(stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;55:1329-1337.
- 13. H. Carol, C. P. Reynolds, M. H. Kang, S. T. Keir, J. M. Maris, R. Gorlick, E. A. Kolb, C. A. Billups, B. Geier, R. T. Kurmasheva, P. J. Houghton, M. A. Smith,
R. B. Lock, Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2013;60:633-641.
- 14. S. Chava, C. P. Reynolds, A. S. Pathania, S. Gorantla, L. Y. Poluektova, D. W. Coulter, S. C. Gupta, M. K. Pandey, K. B. Challagundla, miR-15a-5p, miR-15b-5p,
and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol.
2020;14:180-196.
- 15. N. E. Chen, N. V. Maldonado, V. Khankaldyyan, H. Shimada, M. M. Song, B. J. Maurer, C. P. Reynolds, Reactive Oxygen Species Mediates the Synergistic Activity of
Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. Mol Cancer Ther.
2016;15:2653-2664.
- 16. V. Coothankandaswamy, S. Cao, Y. Xu, P. D. Prasad, P. K. Singh, C. P. Reynolds, S. Yang, J. Ogura, V. Ganapathy, Y. D. Bhutia, Amino acid transporter SLC6A14 is a
novel and effective drug target for pancreatic cancer. Br J Pharmacol.
2016;173:3292-3306.
- 17. R. A. Dagg, H. A. Pickett, A. A. Neumann, C. E. Napier, J. D. Henson, E. T. Teber, J. W. Arthur, C. P. Reynolds, J. Murray, M. Haber, A. P. Sobinoff, L. M. S. Lau,
R. R. Reddel, Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Rep.
2017;19:2544-2556
- 18. L. Donner, T. J. Triche, M. A. Israel, R. C. Seeger, C. P. Reynolds, A panel of monoclonal antibodies which discriminate neuroblastoma from Ewing's sarcoma,
rhabdomyosarcoma, neuroepithelioma, and hematopoietic malignancies. Prog Clin Biol Res. 1985;175:347-366.
- 19. H. Fang, T. M. Harned, O. Kalous, V. Maldonado, Y. A. DeClerck, C. P. Reynolds, Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737
against human neuroblastoma. Clin Cancer Res. 2011;17:7093-7104.
- 20. A. S. Farooqi, R. A. Dagg, L. M. Choi, J. W. Shay, C. P. Reynolds, L. M. Lau, Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack
of MYCN genomic amplification and with p53 pathway aberrations. J Neurooncol.
2014;119:17-26
- 21. K. C. Goldsmith, M. Gross, S. Peirce, D. Luyindula, X. Liu, A. Vu, M. Sliozberg, R. Guo, H. Zhao, C. P. Reynolds, M. D. Hogarty, Mitochondrial Bcl-2 family
dynamics define therapy response and resistance in neuroblastoma. Cancer Res.
2012;72:2565-2577.
- 22. R. Gorlick, E. A. Kolb, P. J. Houghton, C. L. Morton, G. Neale, S. T. Keir, H. Carol, R. Lock, D. Phelps, M. H. Kang, C. P. Reynolds, J. M. Maris, C. Billups,
M. A. Smith, Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59:1266-1274.
- 23. R. Gorlick, E. A. Kolb, P. J. Houghton, C. L. Morton, D. Phelps, P. Schaiquevich, C. Stewart, S. T. Keir, R. Lock, H. Carol, C. P. Reynolds, J. M. Maris, J. Wu, M. A. Smith,
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2009;53:594-598.
- 24. R. Gorlick, E. A. Kolb, S. T. Keir, J. M. Maris, R. B. Lock, H. Carol, C. P. Reynolds, M. H. Kang, C. A. Billups, J. Collins, D. Kurmashev, R. T. Kurmasheva,
P. J. Houghton, M. A. Smith, Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2016;63:443-450.
- 25. R. Gorlick, E. A. Kolb, S. T. Keir, J. M. Maris, C. P. Reynolds, M. H. Kang, H. Carol, R. Lock, C. A. Billups, R. T. Kurmasheva, P. J. Houghton, M. A. Smith,
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2014;61:158-164.
- 26. R. Gorlick, J. M. Maris, P. J. Houghton, R. Lock, H. Carol, R. T. Kurmasheva, E. A. Kolb, S. T. Keir, C. P. Reynolds, M. H. Kang, C. A. Billups, M. A. Smith, Testing of the
Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2012;59:518-524.
- 27. H. Goto, B. Yang, D. Petersen, K. A. Pepper, P. A. Alfaro, D. B. Kohn, C. P. Reynolds, Transduction of green fluorescent protein increased oxidative stress and enhanced
sensitivity to cytotoxic drugs in neuroblastoma cell lines. Mol Cancer Ther. 2003;2:911-917.
- 28. M. D. Hadjidaniel, C. P. Reynolds, Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family
proteins. Mol Cancer Ther. 2010;9:3164-3174.
- 29. N. Hailat, J. Strahler, R. Melhem, X. X. Zhu, G. Brodeur, R. C. Seeger, C. P. Reynolds, S. Hanash, N-myc gene amplification in neuroblastoma is associated with altered
phosphorylation of a proliferation related polypeptide (Op18). Oncogene. 1990;5:1615-1618.
- 30. C. P. Hall, C. P. Reynolds, M. H. Kang, Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with
the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res. 2016;22:621-632.
- 31. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Transcriptomic profiling of 39
commonly-used neuroblastoma cell lines. Sci Data. 2017;4:170033.
- 32. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Corrigendum: Transcriptomic
profiling of 39 commonly-used neuroblastoma cell lines. Sci Data. 2017;4:170183.
- 33. T. M. Harned, O. Kalous, A. Neuwelt, J. Loera, L. Ji, P. Iovine, R. Sposto, E. A. Neuwelt, C. P. Reynolds, Sodium thiosulfate administered six hours after cisplatin
does not compromise antineuroblastoma activity. Clin Cancer Res. 2008;14:533-540.
- 34. R. A. Hazen, M. Eder, D. Drotar, S. Zyzanski, A. E. Reynolds, C. P. Reynolds, E. Kodish, R. B. Noll, A feasibility trial of a video intervention to improve informed
consent for parents of children with leukemia. Pediatr Blood Cancer. 2010;55:113-118.
- 35. P. J. Houghton, R. Gorlick, E. A. Kolb, R. Lock, H. Carol, C. L. Morton, S. T. Keir, C. P. Reynolds, M. H. Kang, D. Phelps, J. M. Maris, C. Billups, M. A. Smith,
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;58:191-199.
- 36. P. J. Houghton, M. H. Kang, C. P. Reynolds, C. L. Morton, E. A. Kolb, R. Gorlick, S. T. Keir, H. Carol, R. Lock, J. M. Maris, C. A. Billups, M. A. Smith, Initial testing
(stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2012;58:636-639.
- 37. P. J. Houghton, R. T. Kurmasheva, D. Lyalin, J. M. Maris, E. A. Kolb, R. Gorlick, C. P. Reynolds, M. H. Kang, S. T. Keir, J. Wu, M. A. Smith, Initial solid tumor testing
(stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2014;61:1972-1979.
- 38. P. J. Houghton, R. Lock, H. Carol, C. L. Morton, R. Gorlick, E. Anders Kolb, S. T. Keir, C. P. Reynolds, M. H. Kang, J. M. Maris, C. A. Billups, M. X. Zhang, S. L. Madden,
B. A. Teicher, M. A. Smith, Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;58:200-209.
- 39. P. J. Houghton, R. Lock, H. Carol, C. L. Morton, D. Phelps, R. Gorlick, E. A. Kolb, S. T. Keir, C. P. Reynolds, M. H. Kang, J. M. Maris, A. W. Wozniak, Y. Gu, W. R. Wilson,
M. A. Smith, Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;57:443-453.
- 40. P. J. Houghton, C. L. Morton, R. Gorlick, E. A. Kolb, S. T. Keir, C. P. Reynolds, M. H. Kang, J. M. Maris, J. Wu, M. A. Smith, Initial testing of a monoclonal antibody
(IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2010;54:921-926.
- 41. P. J. Houghton, C. L. Morton, R. Gorlick, R. B. Lock, H. Carol, C. P. Reynolds, M. H. Kang, J. M. Maris, S. T. Keir, E. A. Kolb, J. Wu, A. W. Wozniak, C. A. Billups,
L. Rubinstein, M. A. Smith, Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther.
2010;9:101-112.
- 42. P. J. Houghton, C. L. Morton, M. Kang, C. P. Reynolds, C. A. Billups, E. Favours, D. Payne-Turner, C. Tucker, M. A. Smith, Evaluation of cytarabine against Ewing sarcoma
xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;55:1224-1226.
- 43. P. J. Houghton, C. L. Morton, E. A. Kolb, R. Gorlick, R. Lock, H. Carol, C. P. Reynolds, J. M. Maris, S. T. Keir, C. A. Billups, M. A. Smith, Initial testing (stage 1) of
the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50:799-805.
- 44. P. J. Houghton, C. L. Morton, E. A. Kolb, R. Lock, H. Carol, C. P. Reynolds, N. Keshelava, J. M. Maris, S. T. Keir, J. Wu, M. A. Smith, Initial testing (stage 1) of the
proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50:37-45.
- 45. P. J. Houghton, C. L. Morton, C. Tucker, D. Payne, E. Favours, C. Cole, R. Gorlick, E. A. Kolb, W. Zhang, R. Lock, H. Carol, M. Tajbakhsh, C. P. Reynolds, J. M. Maris,
J. Courtright, S. T. Keir, H. S. Friedman, C. Stopford, J. Zeidner, J. Wu, T. Liu, C. A. Billups, J. Khan, S. Ansher, J. Zhang, M. A. Smith, The pediatric preclinical testing
program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928-940.
- 46. H. G. Kang, J. M. Jenabi, X. F. Liu, C. P. Reynolds, T. J. Triche, P. H. Sorensen, Inhibition of the insulin-like growth factor I receptor by epigallocatechin
gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther.
2010;9:1396-1407.
- 47. H. G. Kang, J. M. Jenabi, J. Zhang, N. Keshelava, H. Shimada, W. A. May, T. Ng, C. P. Reynolds, T. J. Triche, P. H. Sorensen, E-cadherin cell-cell adhesion in ewing
tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res.
2007;67:3094-3105.
- 48. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP:
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood
110:205-2066, 2007.
- 49. M. H. Kang, C. P. Reynolds, P. J. Houghton, D. Alexander, C. L. Morton, E. A. Kolb, R. Gorlick, S. T. Keir, H. Carol, R. Lock, J. M. Maris, A. Wozniak, M. A. Smith,
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59:185-188.
- 50. M. H. Kang, C. P. Reynolds, E. A. Kolb, R. Gorlick, H. Carol, R. Lock, S. T. Keir, J. M. Maris, J. Wu, D. Lyalin, R. T. Kurmasheva, P. J. Houghton, M. A. Smith,
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2016;63:1744-1752.
- 51. M. H. Kang, C. P. Reynolds, J. M. Maris, R. Gorlick, E. A. Kolb, R. Lock, H. Carol, S. T. Keir, J. Wu, D. Lyalin, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, Initial
testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014;61:1486-1489.
- 52. M. H. Kang, M. A. Smith, C. L. Morton, N. Keshelava, P. J. Houghton, C. P. Reynolds, National Cancer Institute pediatric preclinical testing program: model
description for in vitro cytotoxicity testing. Pediatr Blood Cancer.
2011;56:239-249.
- 53. M. H. Kang, Z. Wan, Y. H. Kang, R. Sposto, C. P. Reynolds, Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines:
Mcl-1 inactivation. J Natl Cancer Inst. 2008;100:580-595.
- 54. M. H. Kang, J. Wang, M. R. Makena, J. S. Lee, N. Paz, C. P. Hall, M. M. Song, R. I. Calderon, R. E. Cruz, A. Hindle, W. Ko, J. B. Fitzgerald, D. C. Drummond,
T. J. Triche, C. P. Reynolds, Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug
and high SLFN11 expression. Clin Cancer Res. 2015;21:1139-1150.
- 55. P. Kapranov, G. St Laurent, T. Raz, F. Ozsolak, C. P. Reynolds, P. H. Sorensen, G. Reaman, P. Milos, R. J. Arceci, J. F. Thompson, T. J. Triche,
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol.
2010;8:149.
- 56. S. T. Keir, J. M. Maris, R. Lock, E. A. Kolb, R. Gorlick, H. Carol, C. L. Morton, C. P. Reynolds, M. H. Kang, A. Watkins, P. J. Houghton, M. A. Smith, Initial testing
(stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;55:1126-1133.
- 57. S. T. Keir, J. M. Maris, C. P. Reynolds, M. H. Kang, E. A. Kolb, R. Gorlick, R. Lock, H. Carol, C. L. Morton, J. Wu, R. T. Kurmasheva, P. J. Houghton, M. A. Smith,
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60:783-790.
- 58. N. Keshelava, E. Davicioni, Z. Wan, L. Ji, R. Sposto, T. J. Triche, C. P. Reynolds, Histone deacetylase 1 gene expression and sensitization of multidrug-resistant
neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst.
2007;99:1107-1119.
- 59. N. Keshelava, S. Groshen, C. P. Reynolds, Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol.
2000;45:1-8.
- 60. N. Keshelava, P. J. Houghton, C. L. Morton, R. B. Lock, H. Carol, S. T. Keir, J. M. Maris, C. P. Reynolds, R. Gorlick, E. A. Kolb, J. Wu, M. A. Smith, Initial testing
(stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2009;53:505-508.
- 61. N. Keshelava, R. C. Seeger, S. Groshen, C. P. Reynolds, Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Cancer Res. 1998;58:5396-5405.
- 62. N. Keshelava, D. Tsao-Wei, C. P. Reynolds, Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res.
2003;9:3492-3502.
- 63. N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, C. P. Reynolds, Loss of p53 function confers high-level multidrug
resistance in neuroblastoma cell lines. Cancer Res. 2001;61:6185-6193.
- 64. E. A. Kolb, R. Gorlick, P. J. Houghton, C. L. Morton, R. Lock, H. Carol, C. P. Reynolds, J. M. Maris, S. T. Keir, C. A. Billups, M. A. Smith, Initial testing
(stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1190-1197.
- 65. E. A. Kolb, R. Gorlick, P. J. Houghton, C. L. Morton, R. B. Lock, M. Tajbakhsh, C. P. Reynolds, J. M. Maris, S. T. Keir, C. A. Billups, M. A. Smith, Initial
testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1198-1206.
- 66. E. A. Kolb, R. Gorlick, P. J. Houghton, C. L. Morton, G. Neale, S. T. Keir, H. Carol, R. Lock, D. Phelps, M. H. Kang, C. P. Reynolds, J. M. Maris,
C. Billups, M. A. Smith, Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2010;55:668-677.
- 67. E. A. Kolb, R. Gorlick, S. T. Keir, J. M. Maris, M. H. Kang, C. P. Reynolds, R. B. Lock, H. Carol, J. Wu, R. T. Kurmasheva, P. J. Houghton, M. A. Smith,
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2015;62:1106-1109.
- 68. E. A. Kolb, R. Gorlick, S. T. Keir, J. M. Maris, R. Lock, H. Carol, R. T. Kurmasheva, C. P. Reynolds, M. H. Kang, J. Wu, P. J. Houghton, M. A. Smith, Initial testing
(stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer.
2012;58:815-818.
- 69. E. A. Kolb, R. Gorlick, C. P. Reynolds, M. H. Kang, H. Carol, R. Lock, S. T. Keir, J. M. Maris, C. A. Billups, C. Desjardins, R. T. Kurmasheva, P. J. Houghton, M. A. Smith,
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60:1325-2.
- 70. B. Koneru, G. Lopez, A. Farooqi, K. L. Conkrite, T. H. Nguyen, S. J. Macha, A. Modi, J. L. Rokita, E. Urias, A. Hindle, H. Davidson, K. McCoy, J. Nance, V. Yazdani,
M. S. Irwin, S. Yang, D. A. Wheeler, J. M. Maris, S. J. Diskin, C. P. Reynolds, Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res.
2020;80:2663-2675.
- 71. K. Krytska, H. T. Ryles, R. Sano, P. Raman, N. R. Infarinato, T. D. Hansel, M. R. Makena, M. M. Song, C. P. Reynolds, Y. P. Mossé, Crizotinib Synergizes with Chemotherapy
in Preclinical Models of Neuroblastoma. Clin Cancer Res. 2016;22:948-960.
- 72. R. T. Kurmasheva, R. Gorlick, E. A. Kolb, S. T. Keir, J. M. Maris, R. B. Lock, H. Carol, M. Kang, C. P. Reynolds, J. Wu, P. J. Houghton, M. A. Smith, Initial testing of
VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2017;64.
- 73. R. T. Kurmasheva, D. Kurmashev, C. P. Reynolds, M. Kang, J. Wu, P. J. Houghton, M. A. Smith, Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor,
alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2018;65.
- 74. R. T. Kurmasheva, C. P. Reynolds, M. H. Kang, C. Allievi, P. J. Houghton, M. A. Smith, Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone,
by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014;61:922-924.
- 75. C. Li, P. A. Einhorn, C. P. Reynolds, Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines. Prog Clin Biol Res.
1994;385:221-227.
- 76. W. Li, Y. Zhang, C. P. Reynolds, D. Pappas, Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human
Transferrin Receptor as a Capture Target. Anal Chem. 2017;89:7340-7347
- 77. T. L. Lochmann, K. M. Powell, J. Ham, K. V. Floros, D. A. R. Heisey, R. I. J. Kurupi, M. L. Calbert, M. S. Ghotra, P. Greninger, M. Dozmorov, M. Gowda, A. J. Souers,
C. P. Reynolds, C. H. Benes, A. C. Faber, Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Sci Transl Med.
2018;10.
- 78. R. Lock, H. Carol, P. J. Houghton, C. L. Morton, E. A. Kolb, R. Gorlick, C. P. Reynolds, J. M. Maris, S. T. Keir, J. Wu, M. A. Smith, Initial testing (stage 1) of the
BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1181-1189.
- 79. R. Lock, H. Carol, J. M. Maris, E. A. Kolb, R. Gorlick, C. P. Reynolds, M. H. Kang, S. T. Keir, J. Wu, A. Purmal, A. Gudkov, D. Kurmashev, R. T. Kurmasheva, P. J. Houghton,
M. A. Smith, Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2017;64.
- 80. R. B. Lock, H. Carol, J. M. Maris, M. H. Kang, C. P. Reynolds, E. A. Kolb, R. Gorlick, S. T. Keir, C. A. Billups, R. T. Kurmasheva, P. J. Houghton, M. A. Smith,
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2013;60:E42-45.
- 81. R. B. Lock, H. Carol, C. L. Morton, S. T. Keir, C. P. Reynolds, M. H. Kang, J. M. Maris, A. W. Wozniak, R. Gorlick, E. A. Kolb, P. J. Houghton, M. A. Smith,
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;58:916-923.
- 82. L. Lopez-Barcons, B. J. Maurer, M. H. Kang, C. P. Reynolds, P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in
human neuroblastoma xenograft models. Int J Cancer. 2017;141:405-413.
- 83. C. D. Lowery, M. Dowless, M. Renschler, W. Blosser, A. B. VanWye, J. R. Stephens, P. W. Iversen, A. B. Lin, R. P. Beckmann, K. Krytska, K. A. Cole, J. M. Maris,
D. S. Hawkins, B. P. Rubin, R. T. Kurmasheva, P. J. Houghton, R. Gorlick, E. A. Kolb, M. H. Kang, C. P. Reynolds, S. W. Erickson, B. A. Teicher, M. A. Smith, L. F. Stancato,
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Clin Cancer Res. 2019;25:2278-2289.
- 84. M. R. Makena, H. E. Cho, T. H. Nguyen, B. Koneru, D. U. Verlekar, A. Hindle, M. H. Kang, C. P. Reynolds, Cytotoxic activity of difluoromethylornithine compared
with fenretinide in neuroblastoma cell lines. Pediatr Blood Cancer. 2018;65:e27447.
- 85. M. R. Makena, B. Koneru, T. H. Nguyen, M. H. Kang, C. P. Reynolds, Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models
of T-cell Lymphoid Malignancies. Mol Cancer Ther. 2017;16:649-661.
- 86. J. M. Maris, J. Courtright, P. J. Houghton, C. L. Morton, R. Gorlick, E. A. Kolb, R. Lock, M. Tajbakhsh, C. P. Reynolds, S. T. Keir, J. Wu, M. A. Smith, Initial
testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:581-587.
- 87. J. M. Maris, J. Courtright, P. J. Houghton, C. L. Morton, E. A. Kolb, R. Lock, M. Tajbakhsh, C. P. Reynolds, S. T. Keir, J. Wu, M. A. Smith, Initial testing
(stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;51:42-48.
- 88. J. M. Maris, C. L. Morton, R. Gorlick, E. A. Kolb, R. Lock, H. Carol, S. T. Keir, C. P. Reynolds, M. H. Kang, J. Wu, M. A. Smith, P. J. Houghton, Initial
testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer.
2010;55:26-34.
- 89. K. K. Matthay, J. G. Villablanca, R. C. Seeger, D. O. Stram, R. E. Harris, N. K. Ramsay, P. Swift, H. Shimada, C. T. Black, G. M. Brodeur, R. B. Gerbing,
C. P. Reynolds, Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid.
Children's Cancer Group. N Engl J Med.
1999;341:1165-1173.
- 90. B. J. Maurer, O. Kalous, D. W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B. C. Sun, R. T. McKee, S. W. Burgess, W. A. Shaw,
C. P. Reynolds, Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res.
2007;13:3079-3086.
- 91. B. J. Maurer, L. S. Metelitsa, R. C. Seeger, M. C. Cabot, C. P. Reynolds, Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-
retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 1999;91:1138-1146.
- 92. W. A. May, R. S. Grigoryan, N. Keshelava, D. J. Cabral, L. L. Christensen, J. Jenabi, L. Ji, T. J. Triche, E. R. Lawlor, C. P. Reynolds, Characterization and
drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One.
2013;8:e80060.
- 93. C. L. Morton, P. J. Houghton, R. Gorlick, E. A. Kolb, R. Lock, H. Carol, S. T. Keir, C. P. Reynolds, M. H. Kang, J. M. Maris, C. Billups, M. A. Smith,
Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer.
2009;53:509-512.
- 94. C. L. Morton, P. J. Houghton, E. A. Kolb, R. Gorlick, C. P. Reynolds, M. H. Kang, J. M. Maris, S. T. Keir, J. Wu, M. A. Smith, Initial testing of the replication competent
Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;55:295-303.
- 95. B. Murphy, H. Yin, J. M. Maris, E. A. Kolb, R. Gorlick, C. P. Reynolds, M. H. Kang, S. T. Keir, R. T. Kurmasheva, I. Dvorchik, J. Wu, C. A. Billups, N. Boateng,
M. A. Smith, R. B. Lock, P. J. Houghton, Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res.
2016;76:5798-5809.
- 96. G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, J. Khoury, T. J. Triche, R. C. Seeger,
R. Gilbertson, J. Khan, M. A. Smith, P. J. Houghton, Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res.
2008;14:4572-4583.
- 97. T. H. Nguyen, B. Koneru, S. J. Wei, W. H. Chen, M. R. Makena, E. Urias, M. H. Kang, C. P. Reynolds, Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2
Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models. Mol Cancer Ther.
2019;18:2270-2282.
- 98. H. Peng, Y. Sohara, R. A. Moats, M. D. Nelson, Jr., S. G. Groshen, W. Ye, C. P. Reynolds, Y. A. DeClerck, The activity of zoledronic Acid on neuroblastoma bone metastasis
involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res.
2007;67:9346-9355.
- 99. C. P. Reynolds, J. L. Biedler, B. A. Spengler, D. A. Reynolds, R. A. Ross, E. P. Frenkel, R. G. Smith, Characterization of human neuroblastoma cell lines established
before and after therapy. J Natl Cancer Inst. 1986;76:375-387.
- 100. C. P. Reynolds, M. H. Kang, H. Carol, R. Lock, R. Gorlick, E. A. Kolb, R. T. Kurmasheva, S. T. Keir, J. M. Maris, C. A. Billups, P. J. Houghton, M. A. Smith, Initial
testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60:791-798.
- 101. C. P. Reynolds, M. H. Kang, S. T. Keir, R. Gorlick, E. A. Kolb, R. Lock, J. M. Maris, H. Carol, C. L. Morton, C. A. Billups, M. A. Smith, P. J. Houghton,
Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;57:606-611.
- 102. C. P. Reynolds, M. H. Kang, J. M. Maris, E. A. Kolb, R. Gorlick, J. Wu, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, Initial testing (stage 1) of the anti-microtubule
agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2015;62:1897-1905.
- 103. C. P. Reynolds, M. M. Tomayko, L. Donner, L. Helson, R. C. Seeger, T. J. Triche, G. M. Brodeur, Biological classification of cell lines derived from human extra-cranial
neural tumors. Prog Clin Biol Res. 1988;271:291-306
- 104. C. P. Reynolds, Y. Wang, L. J. Melton, P. A. Einhorn, D. J. Slamon, B. J. Maurer, Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high
sensitivity to fenretinide. Med Pediatr Oncol.2000;35:597-602.
- 105. J. L. Rokita, K. S. Rathi, M. F. Cardenas, K. A. Upton, J. Jayaseelan, K. L. Cross, J. Pfeil, L. E. Egolf, G. P. Way, A. Farrel, N. M. Kendsersky, K. Patel, K. S.
Gaonkar, A. Modi, E. R. Berko, G. Lopez, Z. Vaksman, C. Mayoh, J. Nance, K. McCoy, M. Haber, K. Evans, H. McCalmont, K. Bendak, J. W. Böhm, G. M. Marshall, V. Tyrrell, K. Kalletla,
F. K. Braun, L. Qi, Y. Du, H. Zhang, H. B. Lindsay, S. Zhao, J. Shu, P. Baxter, C. Morton, D. Kurmashev, S. Zheng, Y. Chen, J. Bowen, A. C. Bryan, K. M. Leraas, S. E. Coppens, H.
Doddapaneni, Z. Momin, W. Zhang, G. I. Sacks, L. S. Hart, K. Krytska, Y. P. Mosse, G. J. Gatto, Y. Sanchez, C. S. Greene, S. J. Diskin, O. M. Vaske, D. Haussler, J. M.
Gastier-Foster, E. A. Kolb, R. Gorlick, X. N. Li, C. P. Reynolds, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, R. B. Lock, P. Raman, D. A. Wheeler, J. M. Maris, Genomic
Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep.
2019;29:1675-1689.e1679.
- 106. N. Rosen, C. P. Reynolds, C. J. Thiele, J. L. Biedler, M. A. Israel, Increased N-myc expression following progressive growth of human neuroblastoma. Cancer Res.
1986;46:4139-4142.
- 107. M. Rosol, I. Harutyunyan, J. Xu, E. Melendez, G. Smbatyan, J. L. Finlay, M. D. Krieger, I. Gonzalez-Gomez, C. P. Reynolds, M. D. Nelson, A. Erdreich-Epstein,
S. Blüml, Metabolism of orthotopic mouse brain tumor models. Mol Imaging. 2009;8:199-208.
- 108. Y. Ryu, C. P. Hall, C. P. Reynolds, M. H. Kang, Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute
lymphoblastic leukemia cell lines. Exp Biol Med (Maywood).
2014;239:1390-1402.
- 109. M. Sausen, R. J. Leary, S. Jones, J. Wu, C. P. Reynolds, X. Liu, A. Blackford, G. Parmigiani, L. A. Diaz, Jr., N. Papadopoulos, B. Vogelstein, K. W. Kinzler,
V. E. Velculescu, M. D. Hogarty, Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet.
2013;45:12-17.
- 110. D. Seidel, A. Shibina, N. Siebert, W. S. Wels, C. P. Reynolds, N. Huebener, H. N. Lode, Disialoganglioside-specific human natural killer cells are effective against
drug-resistant neuroblastoma. Cancer Immunol Immunother. 2015;64:621-634.
- 111. M. A. Sheard, M. V. Ghent, D. J. Cabral, J. C. Lee, V. Khankaldyyan, L. Ji, S. Q. Wu, M. H. Kang, R. Sposto, S. Asgharzadeh, C. P. Reynolds, Preservation of high
glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Exp Cell Res.
2015;334:78-89.
- 112. A. Shibina, D. Seidel, S. S. Somanchi, D. A. Lee, A. Stermann, B. J. Maurer, H. N. Lode, C. P. Reynolds, N. Huebener, Fenretinide sensitizes multidrug-resistant human
neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med (Berl). 2013;91:459-472.
- 113. M. A. Smith, R. Gorlick, E. A. Kolb, R. Lock, H. Carol, J. M. Maris, S. T. Keir, C. L. Morton, C. P. Reynolds, M. H. Kang, J. Arts, T. Bashir, M. Janicot,
R. T. Kurmasheva, P. J. Houghton, Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59:329-332.
- 114. M. A. Smith, O. A. Hampton, C. P. Reynolds, M. H. Kang, J. M. Maris, R. Gorlick, E. A. Kolb, R. Lock, H. Carol, S. T. Keir, J. Wu, R. T. Kurmasheva, D. A. Wheeler,
P. J. Houghton, Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Pediatr Blood Cancer. 2015;62:91-98.
- 115. M. A. Smith, M. H. Kang, C. P. Reynolds, R. T. Kurmasheva, D. Alexander, C. A. Billups, J. A. Toretsky, P. J. Houghton, Evaluation of arsenic trioxide by the pediatric
preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer.
2012;59:753-755.
- 116. M. A. Smith, J. M. Maris, R. Gorlick, E. A. Kolb, R. Lock, H. Carol, S. T. Keir, C. P. Reynolds, M. H. Kang, C. L. Morton, J. Wu, P. G. Smith, J. Yu, P. J. Houghton,
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59:246-253.
- 117. M. A. Smith, J. M. Maris, R. Lock, E. A. Kolb, R. Gorlick, S. T. Keir, H. Carol, C. L. Morton, C. P. Reynolds, M. H. Kang, P. J. Houghton, Initial testing (stage 1)
of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;57:268-274.
- 118. M. A. Smith, C. L. Morton, E. A. Kolb, R. Gorlick, S. T. Keir, H. Carol, R. Lock, M. H. Kang, C. P. Reynolds, J. M. Maris, A. E. Watkins, P. J. Houghton,
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;54:307-310.
- 119. M. A. Smith, C. L. Morton, D. A. Phelps, E. A. Kolb, R. Lock, H. Carol, C. P. Reynolds, J. M. Maris, S. T. Keir, J. Wu, P. J. Houghton, Stage 1 testing and
pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;51:34-41.
- 120. M. A. Smith, C. P. Reynolds, M. H. Kang, E. A. Kolb, R. Gorlick, H. Carol, R. B. Lock, S. T. Keir, J. M. Maris, C. A. Billups, D. Lyalin, R. T. Kurmasheva, P. J. Houghton,
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res.
2015;21:819-832.
- 121. Y. Sohara, H. Shimada, M. Scadeng, H. Pollack, S. Yamada, W. Ye, C. P. Reynolds, Y. A. DeClerck, Lytic bone lesions in human neuroblastoma xenograft involve osteoclast
recruitment and are inhibited by bisphosphonate. Cancer Res. 2003;63:3026-3031.
- 122. P. Sonawane, H. E. Cho, A. Tagde, D. Verlekar, A. L. Yu, C. P. Reynolds, M. H. Kang, Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour
activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br J Pharmacol.
2014;171:5330-5344.
- 123. M. M. Song, M. R. Makena, A. Hindle, B. Koneru, T. H. Nguyen, D. U. Verlekar, H. Cho, B. J. Maurer, M. H. Kang, C. P. Reynolds, Cytotoxicity and molecular activity of
fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. Anticancer Drugs.
2019;30:117-127.
- 124. P. H. Sorensen, J. K. Wu, K. W. Berean, J. F. Lim, W. Donn, H. F. Frierson, C. P. Reynolds, D. López-Terrada, T. J. Triche, Olfactory neuroblastoma is a peripheral
primitive neuroectodermal tumor related to Ewing sarcoma. Proc Natl Acad Sci U S A.
1996;93:1038-1043.
- 125. M. Tajbakhsh, P. J. Houghton, C. L. Morton, E. A. Kolb, R. Gorlick, J. M. Maris, S. T. Keir, J. Wu, C. P. Reynolds, M. A. Smith, R. B. Lock, Initial testing of
cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:992-1000.
- 126. C. J. Thiele, C. P. Reynolds, M. A. Israel, Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature.
1985;313:404-406.
- 127. K. L. Thu, M. Papari-Zareei, V. Stastny, K. Song, M. Peyton, V. D. Martinez, Y. A. Zhang, I. B. Castro, M. Varella-Garcia, H. Liang, C. Xing, R. Kittler, S. Milchgrub,
D. H. Castrillon, H. L. Davidson, C. P. Reynolds, W. L. Lam, J. Lea, A. F. Gazdar, A comprehensively characterized cell line panel highly representative of clinical ovarian
high-grade serous carcinomas. Oncotarget. 2017;8:50489-50499.
- 128. M. M. Tomayko, T. J. Triche, C. P. Reynolds, Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice. Int J Dev
Neurosci. 1996;14:771-777.
- 129. R. M. Trigg, L. C. Lee, N. Prokoph, L. Jahangiri, C. P. Reynolds, G. A. Amos Burke, N. A. Probst, M. Han, J. D. Matthews, H. K. Lim, E. Manners, S. Martinez,
J. Pastor, C. Blanco-Aparicio, O. Merkel, I. G. de Los Fayos Alonso, P. Kodajova, S. Tangermann, S. Högler, J. Luo, L. Kenner, S. D. Turner, The targetable kinase PIM1
drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nat Commun.
2019;10:5428.
- 130. V. Vladimirova, T. Mikeska, A. Waha, N. Soerensen, J. Xu, P. C. Reynolds, T. Pietsch, Aberrant methylation and reduced expression of LHX9 in malignant gliomas of
childhood. Neoplasia. 2009;11:700-711.
- 131. S. L. Volchenboum, C. Li, S. Li, E. F. Attiyeh, C. P. Reynolds, J. M. Maris, A. T. Look, R. E. George, Comparison of primary neuroblastoma tumors and derivative
early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res.
2009;69:4143-4149.
- 132. R. K. Wada, R. C. Seeger, G. M. Brodeur, P. A. Einhorn, S. A. Rayner, M. M. Tomayko, C. P. Reynolds, Human neuroblastoma cell lines that express N-myc without gene
amplification. Cancer. 1993;72:3346-3354.
- 133. R. K. Wada, R. C. Seeger, C. P. Reynolds, T. Alloggiamento, J. M. Yamashiro, C. Ruland, A. C. Black, J. D. Rosenblatt, Cell type-specific expression and negative
regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells. Oncogene. 1992;7:711-717.
- 134. H. Wang, B. J. Maurer, C. P. Reynolds, M. C. Cabot, N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine
palmitoyltransferase and ceramide synthase. Cancer Res. 2001;61:5102-5105.
- 135. S. J. Wei, T. H. Nguyen, I. H. Yang, D. G. Mook, M. R. Makena, D. Verlekar, A. Hindle, G. M. Martinez, S. Yang, H. Shimada, C. P. Reynolds, M. H. Kang,
MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death Dis.
2020;11:368.
- 136. C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, C. P. Reynolds, R. Lock, R. Gorlick,
C. Khanna, C. J. Thiele, M. Takikita, D. Catchpoole, S. M. Hewitt, J. Khan, Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray
analysis. Cancer Res. 2007;67:32-40.
- 137. A. C. Wood, J. M. Maris, R. Gorlick, E. A. Kolb, S. T. Keir, C. P. Reynolds, M. H. Kang, J. Wu, R. T. Kurmasheva, K. Whiteman, P. J. Houghton, M. A. Smith,
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60:1860-1867.
- 138. J. Xu, A. Erdreich-Epstein, I. Gonzalez-Gomez, E. Y. Melendez, G. Smbatyan, R. A. Moats, M. Rosol, J. A. Biegel, C. P. Reynolds, Novel cell lines established
from pediatric brain tumors. J Neurooncol. 2012;107:269-280.
- 139. B. Yang, N. Keshelava, C. P. Anderson, C. P. Reynolds, Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by
the bioreductive agent tirapazamine. Cancer Res. 2003;63:1520-1526.
- 140. B. Yang, C. P. Reynolds, Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. Clin Cancer Res.
2005;11:2774-2780.
- 141. D. Yee, R. E. Favoni, G. S. Lebovic, F. Lombana, D. R. Powell, C. P. Reynolds, N. Rosen, Insulin-like growth factor I expression by tumors of neuroectodermal
origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest.
1990;86:1806-1814.
- 142. A. L. Yu, A. L. Gilman, M. F. Ozkaynak, W. B. London, S. G. Kreissman, H. X. Chen, M. Smith, B. Anderson, J. G. Villablanca, K. K. Matthay, H. Shimada, S. A. Grupp,
R. Seeger, C. P. Reynolds, A. Buxton, R. A. Reisfeld, S. D. Gillies, S. L. Cohn, J. M. Maris, P. M. Sondel, Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for
neuroblastoma. N Engl J Med. 2010;363:1324-1334.
- 143. Maurer BJ, Cabot MC, Reynolds CP: Synergistic cytotoxicity in solid tumor cell lines of N-(4-hydroxypheynl)retinamide and modulators of ceramide metabolism.
J National Cancer Institute 92:1897-1908, 2000. PMID: 11106681
- 144. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS: Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other
tumor suppressor loci in neuroblastoma. Cancer Research 61:679-758, 2001.
- 145. Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC: Enhanced expression and activation of Mac-1 (CD11b/CD18) by an anti-GD2/GM-CSF fusion
protein increases neutrophil antibody dependent cellular cytotoxicity. Blood
99:4166-4173, 2002.
- 146. Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O’Malley JP, Hsieh YC, Turner MA, Wang Z, Tian Q, Rodland MJ, Reynolds CP, Seeger RC, Niagalla R:
GABAnergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clinical Oncology
22:4127-4134, 2004.
- 147. Grigoryan RS, Yang B, Keshelava N, Barnhart JR, Reynolds CP: Flow cytometry analysis of single strand DNA damage in neuroblastoma cell lines using the F7-26
monoclonal antibody. Cytometry Part A 71A:951-960, 2007.
- 148. Batra S, Reynolds CP, Maurer BJ: Fenretinide cytotoxicity for Ewing’s sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by
hypoxia and synergistically enhanced by ceramide modulators. Cancer Research
64:5415-5424, 2004.
- 149. Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, Lock R, Carol H, Keir S, Billups C, Kurmasheva R, Houghton P. Abstract C206: Pediatric Preclinical Testing Program
(PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ). Molecular Cancer Therapeutics.
2013;12(11 Supplement):C206-C206
- 150. May WA, Grigoryan RS, Keshelava N, Cabral JD, Christensen LL, Jenabi J, Ji L, Lawlor ER, Reynolds CP: Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLOS One Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060, 2013. PMID: 24312454
- 151. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J,
Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors.
J Neurooncology 107:269-80, 2012. PMID: 22120608
- 152. Sheard MA, Ghent MV, Kang MH, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Sposto R, Asgharzadeh S, Reynolds
CP: The Warburg effect is preserved by establishing new childhood acute
lymphoblastic leukemia cell lines in physiologic oxygen tension. Exp Cell Res 334:78-89, 2015.
PMID:25845499
- 153. Kolb EA, Gorlick R, Houghton PJ, Morton C, Maris JM, Courtright J, Carol H, Lock R, Friedman HS, Keir ST, M.H. K, Reynolds CP, Smith MA. Pediatric
Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor sorafenib. Proc Amer Assoc Cancer Res.
2009;50:3196-3196. Not in File.
- 154. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the
IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;56(4):595-603. Not in File. doi:10.1002/pbc.22741 [doi]
Characterization of Neuroblastoma Cell Lines
- 2. C. P. Anderson, C. P. Reynolds, Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant. 2002;30:135-140.
- 3. C. P. Anderson, R. C. Seeger, N. Satake, H. L. Monforte-Munoz, N. Keshelava, H. H. Bailey, C. P. Reynolds, Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol. 2001;23:500-505.
- 18. R. A. Dagg, H. A. Pickett, A. A. Neumann, C. E. Napier, J. D. Henson, E. T. Teber, J. W. Arthur, C. P. Reynolds, J. Murray, M. Haber, A. P. Sobinoff, L. M. S. Lau, R. R. Reddel, Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Rep. 2017;19:2544-2556
- 21. A. S. Farooqi, R. A. Dagg, L. M. Choi, J. W. Shay, C. P. Reynolds, L. M. Lau, Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. J Neurooncol. 2014;119:17-26
- 22. K. C. Goldsmith, M. Gross, S. Peirce, D. Luyindula, X. Liu, A. Vu, M. Sliozberg, R. Guo, H. Zhao, C. P. Reynolds, M. D. Hogarty, Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 2012;72:2565-2577.
- 31. C. P. Hall, C. P. Reynolds, M. H. Kang, Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res. 2016;22:621-632.
- 32. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data. 2017;4:170033.
- 33. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data. 2017;4:170183
- 54. M. H. Kang, M. A. Smith, C. L. Morton, N. Keshelava, P. J. Houghton, C. P. Reynolds, National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer. 2011;56:239-249.
- 60. N. Keshelava, E. Davicioni, Z. Wan, L. Ji, R. Sposto, T. J. Triche, C. P. Reynolds, Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst. 2007;99:1107-1119.
- 63. N. Keshelava, R. C. Seeger, S. Groshen, C. P. Reynolds, Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 1998;58:5396-5405.
- 65. N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, C. P. Reynolds, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001;61:6185-6193.
- 77. C. Li, P. A. Einhorn, C. P. Reynolds, Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines. Prog Clin Biol Res. 1994;385:221-227.
- 98. G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, J. Khoury, T. J. Triche, R. C. Seeger, R. Gilbertson, J. Khan, M. A. Smith, P. J. Houghton, Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008;14:4572-4583.
- 101. C. P. Reynolds, J. L. Biedler, B. A. Spengler, D. A. Reynolds, R. A. Ross, E. P. Frenkel, R. G. Smith, Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst. 1986;76:375-387.
- 105. C. P. Reynolds, M. M. Tomayko, L. Donner, L. Helson, R. C. Seeger, T. J. Triche, G. M. Brodeur, Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res. 1988;271:291-306
- 130. M. M. Tomayko, T. J. Triche, C. P. Reynolds, Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice. Int J Dev Neurosci. 1996;14:771-777.
- 133. S. L. Volchenboum, C. Li, S. Li, E. F. Attiyeh, C. P. Reynolds, J. M. Maris, A. T. Look, R. E. George, Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009;69:4143-4149.
- 134. R. K. Wada, R. C. Seeger, G. M. Brodeur, P. A. Einhorn, S. A. Rayner, M. M. Tomayko, C. P. Reynolds, Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer. 1993;72:3346-3354.
- 137 S. J. Wei, T. H. Nguyen, I. H. Yang, D. G. Mook, M. R. Makena, D. Verlekar, A. Hindle, G. M. Martinez, S. Yang, H. Shimada, C. P. Reynolds, M. H. Kang, MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death Dis. 2020;11:368.
- 138. C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, C. P. Reynolds, R. Lock, R. Gorlick, C. Khanna, C. J. Thiele, M. Takikita, D. Catchpoole, S. M. Hewitt, J. Khan, Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007;67:32-40.
Characterization of other Childhood Cancer Cell Lines
- 150. May WA, Grigoryan RS, Keshelava N, Cabral JD, Christensen LL, Jenabi J, Ji L, Lawlor ER, Reynolds CP: Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLOS One Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060, 2013. PMID: 24312454
- 151. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology 107:269-80, 2012. PMID: 22120608
- 152. Sheard MA, Ghent MV, Kang MH, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Sposto R, Asgharzadeh S, Reynolds CP: The Warburg effect is preserved by establishing new childhood acute lymphoblastic leukemia cell lines in physiologic oxygen tension. Exp Cell Res 334:78-89, 2015. PMID:25845499
Research Using Neuroblastoma Cell Lines and PDXs
- 2. C. P. Anderson, C. P. Reynolds, Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant. 2002;30:135-140.
- 3. C. P. Anderson, R. C. Seeger, N. Satake, H. L. Monforte-Munoz, N. Keshelava, H. H. Bailey, C. P. Reynolds, Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol. 2001;23:500-505.
- 4. C. P. Anderson, J. M. Tsai, W. E. Meek, R. M. Liu, Y. Tang, H. J. Forman, C. P. Reynolds, Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res. 1999;246:183-192.
- 7. W. Cai, N. V. Maldonado, W. Cui, N. Harutyunyan, L. Ji, R. Sposto, C. P. Reynolds, N. Keshelava, Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer. 2010;103:1369-1379.
- 15. S. Chava, C. P. Reynolds, A. S. Pathania, S. Gorantla, L. Y. Poluektova, D. W. Coulter, S. C. Gupta, M. K. Pandey, K. B. Challagundla, miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2020;14:180-196.
- 16. N. E. Chen, N. V. Maldonado, V. Khankaldyyan, H. Shimada, M. M. Song, B. J. Maurer, C. P. Reynolds, Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. Mol Cancer Ther. 2016;15:2653-2664.
- 18. R. A. Dagg, H. A. Pickett, A. A. Neumann, C. E. Napier, J. D. Henson, E. T. Teber, J. W. Arthur, C. P. Reynolds, J. Murray, M. Haber, A. P. Sobinoff, L. M. S. Lau, R. R. Reddel, Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Rep. 2017;19:2544-2556.
- 19. L. Donner, T. J. Triche, M. A. Israel, R. C. Seeger, C. P. Reynolds, A panel of monoclonal antibodies which discriminate neuroblastoma from Ewing's sarcoma, rhabdomyosarcoma, neuroepithelioma, and hematopoietic malignancies. Prog Clin Biol Res. 1985;175:347-366.
- 20. H. Fang, T. M. Harned, O. Kalous, V. Maldonado, Y. A. DeClerck, C. P. Reynolds, Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clin Cancer Res. 2011;17:7093-7104.
- 21. A. S. Farooqi, R. A. Dagg, L. M. Choi, J. W. Shay, C. P. Reynolds, L. M. Lau, Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. J Neurooncol. 2014;119:17-26.
- 22. K. C. Goldsmith, M. Gross, S. Peirce, D. Luyindula, X. Liu, A. Vu, M. Sliozberg, R. Guo, H. Zhao, C. P. Reynolds, M. D. Hogarty, Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 2012;72:2565-2577.
- 28. H. Goto, B. Yang, D. Petersen, K. A. Pepper, P. A. Alfaro, D. B. Kohn, C. P. Reynolds, Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines. Mol Cancer Ther. 2003;2:911-917.
- 29. M. D. Hadjidaniel, C. P. Reynolds, Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2010;9:3164-3174.
- 30. N. Hailat, J. Strahler, R. Melhem, X. X. Zhu, G. Brodeur, R. C. Seeger, C. P. Reynolds, S. Hanash, N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). Oncogene. 1990;5:1615-1618.
- 32. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data. 2017;4:170033.
- 33. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data. 2017;4:170183.
- 34. T. M. Harned, O. Kalous, A. Neuwelt, J. Loera, L. Ji, P. Iovine, R. Sposto, E. A. Neuwelt, C. P. Reynolds, Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin Cancer Res. 2008;14:533-540.
- 54. M. H. Kang, M. A. Smith, C. L. Morton, N. Keshelava, P. J. Houghton, C. P. Reynolds, National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer. 2011;56:239-249.
- 56. M. H. Kang, J. Wang, M. R. Makena, J. S. Lee, N. Paz, C. P. Hall, M. M. Song, R. I. Calderon, R. E. Cruz, A. Hindle, W. Ko, J. B. Fitzgerald, D. C. Drummond, T. J. Triche, C. P. Reynolds, Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015;21:1139-1150.
- 60. N. Keshelava, E. Davicioni, Z. Wan, L. Ji, R. Sposto, T. J. Triche, C. P. Reynolds, Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst. 2007;99:1107-1119.
- 61. N. Keshelava, S. Groshen, C. P. Reynolds, Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol. 2000;45:1-8.
- 63. N. Keshelava, R. C. Seeger, S. Groshen, C. P. Reynolds, Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 1998;58:5396-5405.
- 64. N. Keshelava, D. Tsao-Wei, C. P. Reynolds, Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res. 2003;9:3492-3502.
- 65. N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, C. P. Reynolds, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001;61:6185-6193.
- 72. B. Koneru, G. Lopez, A. Farooqi, K. L. Conkrite, T. H. Nguyen, S. J. Macha, A. Modi, J. L. Rokita, E. Urias, A. Hindle, H. Davidson, K. McCoy, J. Nance, V. Yazdani, M. S. Irwin, S. Yang, D. A. Wheeler, J. M. Maris, S. J. Diskin, C. P. Reynolds, Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res. 2020;80:2663-2675.
- 73. K. Krytska, H. T. Ryles, R. Sano, P. Raman, N. R. Infarinato, T. D. Hansel, M. R. Makena, M. M. Song, C. P. Reynolds, Y. P. Mossé, Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. Clin Cancer Res. 2016;22:948-960.
- 77. C. Li, P. A. Einhorn, C. P. Reynolds, Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines. Prog Clin Biol Res. 1994;385:221-227.
- 79. T. L. Lochmann, K. M. Powell, J. Ham, K. V. Floros, D. A. R. Heisey, R. I. J. Kurupi, M. L. Calbert, M. S. Ghotra, P. Greninger, M. Dozmorov, M. Gowda, A. J. Souers, C. P. Reynolds, C. H. Benes, A. C. Faber, Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Sci Transl Med. 2018;10.
- 84. L. Lopez-Barcons, B. J. Maurer, M. H. Kang, C. P. Reynolds, P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. Int J Cancer. 2017;141:405-413.
- 86. M. R. Makena, H. E. Cho, T. H. Nguyen, B. Koneru, D. U. Verlekar, A. Hindle, M. H. Kang, C. P. Reynolds, Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines. Pediatr Blood Cancer. 2018;65:e27447.
- 92. B. J. Maurer, O. Kalous, D. W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B. C. Sun, R. T. McKee, S. W. Burgess, W. A. Shaw, C. P. Reynolds, Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res. 2007;13:3079-3086.
- 93. B. J. Maurer, L. S. Metelitsa, R. C. Seeger, M. C. Cabot, C. P. Reynolds, Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 1999;91:1138-1146.
- 99. T. H. Nguyen, B. Koneru, S. J. Wei, W. H. Chen, M. R. Makena, E. Urias, M. H. Kang, C. P. Reynolds, Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models. Mol Cancer Ther. 2019;18:2270-2282.
- 100. H. Peng, Y. Sohara, R. A. Moats, M. D. Nelson, Jr., S. G. Groshen, W. Ye, C. P. Reynolds, Y. A. DeClerck, The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res. 2007;67:9346-9355.
- 101. C. P. Reynolds, J. L. Biedler, B. A. Spengler, D. A. Reynolds, R. A. Ross, E. P. Frenkel, R. G. Smith, Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst. 1986;76:375-387.
- 105. C. P. Reynolds, M. M. Tomayko, L. Donner, L. Helson, R. C. Seeger, T. J. Triche, G. M. Brodeur, Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res. 1988;271:291-306.
- 106. C. P. Reynolds, Y. Wang, L. J. Melton, P. A. Einhorn, D. J. Slamon, B. J. Maurer, Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol. 2000;35:597-602.
- 107. J. L. Rokita, K. S. Rathi, M. F. Cardenas, K. A. Upton, J. Jayaseelan, K. L. Cross, J. Pfeil, L. E. Egolf, G. P. Way, A. Farrel, N. M. Kendsersky, K. Patel, K. S. Gaonkar, A. Modi, E. R. Berko, G. Lopez, Z. Vaksman, C. Mayoh, J. Nance, K. McCoy, M. Haber, K. Evans, H. McCalmont, K. Bendak, J. W. Böhm, G. M. Marshall, V. Tyrrell, K. Kalletla, F. K. Braun, L. Qi, Y. Du, H. Zhang, H. B. Lindsay, S. Zhao, J. Shu, P. Baxter, C. Morton, D. Kurmashev, S. Zheng, Y. Chen, J. Bowen, A. C. Bryan, K. M. Leraas, S. E. Coppens, H. Doddapaneni, Z. Momin, W. Zhang, G. I. Sacks, L. S. Hart, K. Krytska, Y. P. Mosse, G. J. Gatto, Y. Sanchez, C. S. Greene, S. J. Diskin, O. M. Vaske, D. Haussler, J. M. Gastier-Foster, E. A. Kolb, R. Gorlick, X. N. Li, C. P. Reynolds, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, R. B. Lock, P. Raman, D. A. Wheeler, J. M. Maris, Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019;29:1675-1689.e1679.
- 108. N. Rosen, C. P. Reynolds, C. J. Thiele, J. L. Biedler, M. A. Israel, Increased N-myc expression following progressive growth of human neuroblastoma. Cancer Res. 1986;46:4139-4142.
- 111. M. Sausen, R. J. Leary, S. Jones, J. Wu, C. P. Reynolds, X. Liu, A. Blackford, G. Parmigiani, L. A. Diaz, Jr., N. Papadopoulos, B. Vogelstein, K. W. Kinzler, V. E. Velculescu, M. D. Hogarty, Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45:12-17.
- 112. D. Seidel, A. Shibina, N. Siebert, W. S. Wels, C. P. Reynolds, N. Huebener, H. N. Lode, Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol Immunother. 2015;64:621-634.
- 114. A. Shibina, D. Seidel, S. S. Somanchi, D. A. Lee, A. Stermann, B. J. Maurer, H. N. Lode, C. P. Reynolds, N. Huebener, Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med (Berl). 2013;91:459-472.
- 123. Y. Sohara, H. Shimada, M. Scadeng, H. Pollack, S. Yamada, W. Ye, C. P. Reynolds, Y. A. DeClerck, Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res. 2003;63:3026-3031.
- 124. P. Sonawane, H. E. Cho, A. Tagde, D. Verlekar, A. L. Yu, C. P. Reynolds, M. H. Kang, Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br J Pharmacol. 2014;171:5330-5344.
- 125. M. M. Song, M. R. Makena, A. Hindle, B. Koneru, T. H. Nguyen, D. U. Verlekar, H. Cho, B. J. Maurer, M. H. Kang, C. P. Reynolds, Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. Anticancer Drugs. 2019;30:117-127.
- 128. C. J. Thiele, C. P. Reynolds, M. A. Israel, Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature. 1985;313:404-406.
- 130. M. M. Tomayko, T. J. Triche, C. P. Reynolds, Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice. Int J Dev Neurosci. 1996;14:771-777.
- 131. R. M. Trigg, L. C. Lee, N. Prokoph, L. Jahangiri, C. P. Reynolds, G. A. Amos Burke, N. A. Probst, M. Han, J. D. Matthews, H. K. Lim, E. Manners, S. Martinez, J. Pastor, C. Blanco-Aparicio, O. Merkel, I. G. de Los Fayos Alonso, P. Kodajova, S. Tangermann, S. Högler, J. Luo, L. Kenner, S. D. Turner, The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nat Commun. 2019;10:5428.
- 133. S. L. Volchenboum, C. Li, S. Li, E. F. Attiyeh, C. P. Reynolds, J. M. Maris, A. T. Look, R. E. George, Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009;69:4143-4149.
- 134. R. K. Wada, R. C. Seeger, G. M. Brodeur, P. A. Einhorn, S. A. Rayner, M. M. Tomayko, C. P. Reynolds, Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer. 1993;72:3346-3354.
- 135. R. K. Wada, R. C. Seeger, C. P. Reynolds, T. Alloggiamento, J. M. Yamashiro, C. Ruland, A. C. Black, J. D. Rosenblatt, Cell type-specific expression and negative regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells. Oncogene. 1992;7:711-717.
- 136. H. Wang, B. J. Maurer, C. P. Reynolds, M. C. Cabot, N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res. 2001;61:5102-5105.
- 137. S. J. Wei, T. H. Nguyen, I. H. Yang, D. G. Mook, M. R. Makena, D. Verlekar, A. Hindle, G. M. Martinez, S. Yang, H. Shimada, C. P. Reynolds, M. H. Kang, MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death Dis. 2020;11:368.
- 138. C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, C. P. Reynolds, R. Lock, R. Gorlick, C. Khanna, C. J. Thiele, M. Takikita, D. Catchpoole, S. M. Hewitt, J. Khan, Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007;67:32-40.
- 141. B. Yang, N. Keshelava, C. P. Anderson, C. P. Reynolds, Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res. 2003;63:1520-1526.
- 142. B. Yang, C. P. Reynolds, Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. Clin Cancer Res. 2005;11:2774-2780.
- 145. Maurer BJ, Cabot MC, Reynolds CP: Synergistic cytotoxicity in solid tumor cell lines of N-(4-hydroxypheynl)retinamide and modulators of ceramide metabolism. J National Cancer Institute 92:1897-1908, 2000. PMID: 11106681
- 146. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS: Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Research 61:679-758, 2001.
- 147. Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC: Enhanced expression and activation of Mac-1 (CD11b/CD18) by an anti-GD2/GM-CSF fusion protein increases neutrophil antibody dependent cellular cytotoxicity. Blood 99:4166-4173, 2002.
- 148. Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O’Malley JP, Hsieh YC, Turner MA, Wang Z, Tian Q, Rodland MJ, Reynolds CP, Seeger RC, Niagalla R: GABAnergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clinical Oncology 22:4127-4134, 2004.
- 149. Grigoryan RS, Yang B, Keshelava N, Barnhart JR, Reynolds CP: Flow cytometry analysis of single strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. Cytometry Part A 71A:951-960, 2007.
Research Using Leukemia Cell Lines and PDXs
- 31. C. P. Hall, C. P. Reynolds, M. H. Kang, Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM
Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res. 2016;22:621-632.
- 50. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP:
Activity
of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood
110:205-2066, 2007.
- 54. M. H. Kang, M. A. Smith, C. L. Morton, N. Keshelava, P. J. Houghton, C. P. Reynolds, National Cancer Institute pediatric preclinical testing program:
model description for in vitro cytotoxicity testing. Pediatr Blood Cancer.
2011;56:239-249.
- 55. M. H. Kang, Z. Wan, Y. H. Kang, R. Sposto, C. P. Reynolds, Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia
cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008;100:580-595.
- 78. W. Li, Y. Zhang, C. P. Reynolds, D. Pappas, Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human
Transferrin Receptor as a Capture Target. Anal Chem. 2017;89:7340-7347
- 87. M. R. Makena, B. Koneru, T. H. Nguyen, M. H. Kang, C. P. Reynolds, Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical
Models of T-cell Lymphoid Malignancies. Mol Cancer Ther. 2017;16:649-661.
- 98. G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, J. Khoury, T. J. Triche, R. C.
Seeger, R. Gilbertson, J. Khan, M. A. Smith, P. J. Houghton, Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res.
2008;14:4572-4583.
- 110. Y. Ryu, C. P. Hall, C. P. Reynolds, M. H. Kang, Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in
human acute lymphoblastic leukemia cell lines. Exp Biol Med (Maywood).
2014;239:1390-1402.
- 113. M. A. Sheard, M. V. Ghent, D. J. Cabral, J. C. Lee, V. Khankaldyyan, L. Ji, S. Q. Wu, M. H. Kang, R. Sposto, S. Asgharzadeh, C. P. Reynolds, Preservation
of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.
Exp Cell Res. 2015;334:78-89.
Research Using EFT Cell Lines
- 19. L. Donner, T. J. Triche, M. A. Israel, R. C. Seeger, C. P. Reynolds, A panel of monoclonal antibodies which discriminate neuroblastoma from Ewing's
sarcoma, rhabdomyosarcoma, neuroepithelioma, and hematopoietic malignancies. Prog Clin Biol Res.1985;175:347-366.
- 48. H. G. Kang, J. M. Jenabi, X. F. Liu, C. P. Reynolds, T. J. Triche, P. H. Sorensen, Inhibition of the insulin-like growth factor I receptor by
epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther.
2010;9:1396-1407.
- 49. H. G. Kang, J. M. Jenabi, J. Zhang, N. Keshelava, H. Shimada, W. A. May, T. Ng, C. P. Reynolds, T. J. Triche, P. H. Sorensen, E-cadherin cell-cell
adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res.
2007;67:3094-3105.
- 54. M. H. Kang, M. A. Smith, C. L. Morton, N. Keshelava, P. J. Houghton, C. P. Reynolds, National Cancer Institute pediatric preclinical testing program:
model description for in vitro cytotoxicity testing. Pediatr Blood Cancer.
2011;56:239-249.
- 56. M. H. Kang, J. Wang, M. R. Makena, J. S. Lee, N. Paz, C. P. Hall, M. M. Song, R. I. Calderon, R. E. Cruz, A. Hindle, W. Ko, J. B. Fitzgerald,
D. C. Drummond, T. J. Triche, C. P. Reynolds, Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with
high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res.
2015;21:1139-1150.
- 57. P. Kapranov, G. St Laurent, T. Raz, F. Ozsolak, C. P. Reynolds, P. H. Sorensen, G. Reaman, P. Milos, R. J. Arceci, J. F. Thompson, T. J. Triche,
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol.
2010;8:149.
- 94. W. A. May, R. S. Grigoryan, N. Keshelava, D. J. Cabral, L. L. Christensen, J. Jenabi, L. Ji, T. J. Triche, E. R. Lawlor, C. P. Reynolds,
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One.
2013;8:e80060.
- 98. G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, J. Khoury, T. J. Triche,
R. C. Seeger, R. Gilbertson, J. Khan, M. A. Smith, P. J. Houghton, Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res.
2008;14:4572-4583.
- 105. C. P. Reynolds, M. M. Tomayko, L. Donner, L. Helson, R. C. Seeger, T. J. Triche, G. M. Brodeur, Biological classification of cell lines derived
from human extra-cranial neural tumors. Prog Clin Biol Res. 1988;271:291-306.
- 138. C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, C. P. Reynolds,
R. Lock, R. Gorlick, C. Khanna, C. J. Thiele, M. Takikita, D. Catchpoole, S. M. Hewitt, J. Khan, Credentialing preclinical pediatric xenograft models using
gene expression and tissue microarray analysis. Cancer Res.
2007;67:32-40.
- 150. Batra S, Reynolds CP, Maurer BJ: Fenretinide cytotoxicity for Ewing’s sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is
decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research
64:5415-5424, 2004.
Characterization and research of Brain tumor
- 52. M. H. Kang, M. A. Smith, C. L. Morton, N. Keshelava, P. J. Houghton, C. P. Reynolds, National Cancer Institute pediatric preclinical testing program:
model description for in vitro cytotoxicity testing. Pediatr Blood Cancer.
2011;56:239-249.
- 96. G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, J. Khoury, T. J. Triche,
R. C. Seeger, R. Gilbertson, J. Khan, M. A. Smith, P. J. Houghton, Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res.
2008;14:4572-4583.
- 107. M. Rosol, I. Harutyunyan, J. Xu, E. Melendez, G. Smbatyan, J. L. Finlay, M. D. Krieger, I. Gonzalez-Gomez, C. P. Reynolds, M. D. Nelson,
A. Erdreich-Epstein, S. Blüml, Metabolism of orthotopic mouse brain tumor models. Mol Imaging. 2009;8:199-208.
- 136. C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, C. P. Reynolds,
R. Lock, R. Gorlick, C. Khanna, C. J. Thiele, M. Takikita, D. Catchpoole, S. M. Hewitt, J. Khan, Credentialing preclinical pediatric xenograft models using gene
expression and tissue microarray analysis. Cancer Res.
2007;67:32-40.
- 138. J. Xu, A. Erdreich-Epstein, I. Gonzalez-Gomez, E. Y. Melendez, G. Smbatyan, R. A. Moats, M. Rosol, J. A. Biegel, C. P. Reynolds, Novel cell lines
established from pediatric brain tumors. J Neurooncol.
2012;107:269-280.
NCI Pediatric Preclinical Testing Program
- 5. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA. Initial testing
(stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59(4):749-752. Not in File.
doi:10.1002/pbc.23364 [doi]
- 8. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ,
Smith MA, Lock R. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
Pediatr Blood Cancer.
2014;61(2):245-252. Not in File. doi:10.1002/pbc.24724 [doi]
- 9. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB. Initial testing of
topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;54(5):707-715. Not in File. doi:10.1002/pbc.22352 [doi]
- 10. Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the
kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2009;53(7):1255-1263. Not in File. doi:10.1002/pbc.22056 [doi]
- 11. Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing
(stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2014;Not in File. doi:10.1002/pbc.25026 [doi]
- 12. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB. Initial testing (stage 1)
of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer
. 2010;55(7):1329-1337. Not in File. doi:10.1002/pbc.22710 [doi]
- 13. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing
of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2013;60(4):633-641. Not in File. doi:10.1002/pbc.24235 [doi]
- 22. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA.
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59(7):1266-1274. Not in File. doi:10.1002/pbc.24073 [doi]
- 23. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA.
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2009;53(4):594-598. Not in File. doi:10.1002/pbc.21989 [doi]
- 25. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1)
of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2014;61(1):158-164. Not in File. doi:10.1002/pbc.24616 [doi]
- 26. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA. Testing of the
Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2012;59(3):518-524. Not in File. doi:10.1002/pbc.23412 [doi]
- 90. Houghton P, Morton C, Maris JM, Courtright J, Carol H, Lock R, Friedman HS, Keir ST, Gorlick R, Kolb EA, Reynolds CP, Kang MH, Smith.M.A. Pediatric
Preclinical Testing Program (PPTP) evaluation of the Aurora A Kinase Inhibitor MLN8237. Am Assoc Cancer Res.
2008;49:2997. Not in File.
- 35. Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA.
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;58(2):191-199. Not in File. doi:10.1002/pbc.22935 [doi]
- 37. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA. Initial
testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2012;58(4):636-639. Not in File. doi:10.1002/pbc.23167 [doi]
- 38. Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders KE, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL,
Teicher BA, Smith MA. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;58(2):200-209. Not in File. doi:10.1002/pbc.23016 [doi]
- 39. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR,
Smith MA. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;57(3):443-453. Not in File. doi:10.1002/pbc.22921 [doi]
- 40. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA. Initial testing of a monoclonal antibody
(IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2010;54(7):921-926. Not in File. doi:10.1002/pbc.22367 [doi]
- 41. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L,
Smith MA. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther.
2010;9(1):101-112. Not in File.
- 42. Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA. Evaluation of cytarabine against Ewing
sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;55(6):1224-1226. Not in File. doi:10.1002/pbc.22355 [doi]
- 43. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the
mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50(4):799-805. Not in File. doi:10.1002/pbc.21296 [doi]
- 45. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the proteasome
inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50(1):37-45. Not in File.
- 43. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM,
Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. The pediatric
preclinical testing program: description of models and early testing results. Pediatr Blood Cancer.
2007;49(7):928-940. Not in File. doi:10.1002/pbc.21078 [doi]
- 49. Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA. Initial testing
(Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59(1):185-188. Not in File. doi:10.1002/pbc.23154 [doi]
- 51. Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing
(stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2014;Not in File. doi:10.1002/pbc.24989 [doi]
- 52. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description
for in vitro cytotoxicity testing. Pediatr Blood Cancer.
2011;56(2):239-249. Not in File. doi:10.1002/pbc.22801 [doi]
- 56. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA. Initial testing (stage 1)
of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;55(6):1126-1133. Not in File. doi:10.1002/pbc.22712 [doi]
- 57. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing
(stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60(5):783-790. Not in File. doi:10.1002/pbc.24368 [doi]
- 58. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1)
of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2009;53(3):505-508. Not in File.
- 64. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of a monoclonal
antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50(6):1190-1197. Not in File. doi:10.1002/pbc.21450 [doi]
- 65. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing of dasatinib by the
pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50(6):1198-1206. Not in File.
- 66. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial
testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2010;55(4):668-677. Not in File. doi:10.1002/pbc.22576 [doi]
- 68. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) by
the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer.
2012;58(5):815-818. Not in File. doi:10.1002/pbc.23290 [doi]
- 69. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing
(stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60(8):1325-1332. Not in File. doi:10.1002/pbc.24517 [doi]
- 74. Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the
pediatric preclinical testing program. Pediatr Blood Cancer.
2014;61(5):922-924. Not in File. doi:10.1002/pbc.24800 [doi]
- 78. Lock R, Carol H, Houghton P, Morton C, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, MA S. Initial testing (stage 1) of the BH3 mimetic ABT-263
by the pediatric preclinical testing program. Pediatric blood & cancer.
2008;50(6):1181-1189. Not in File.
- 80. Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1)
of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2013;60(7):E42-E45. Not in File. doi:10.1002/pbc.24451 [doi]
- 81. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E
inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;58(6):916-923. Not in File. doi:10.1002/pbc.23176 [doi]
- 86. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing of the VEGFR
inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50(3):581-587. Not in File. doi:10.1002/pbc.21232 [doi]
- 87. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by
the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;51(1):42-48. Not in File. doi:10.1002/pbc.21535 [doi]
- 88. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ. Initial testing of the aurora kinase
A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer.
2010;55(1):26-34. Not in File. doi:10.1002/pbc.22430 [doi]
- 94. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA. Initial testing of the replication competent Seneca
Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;55(2):295-303. Not in File. doi:10.1002/pbc.22535 [doi]
- 100. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA. Initial testing (stage 1)
of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60(5):791-798. Not in File. doi:10.1002/pbc.24301 [doi]
- 101. Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ. Initial testing of
lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;57(4):606-611. Not in File. doi:10.1002/pbc.22877 [doi]
- 113. Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT,
Houghton PJ. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59(2):329-332. Not in File. doi:10.1002/pbc.23319 [doi]
- 114. Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA,
Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional
in vivo response to BMN 673. Pediatr Blood Cancer.
2015;62(1):91-98. Not in File. doi:10.1002/pbc.25201 [doi]
- 115. Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJ. Evaluation of arsenic trioxide by the pediatric
preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer.
2012;59(4):753-755. Not in File. doi:10.1002/pbc.23391 [doi]
- 116. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ. Initial testing
of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2012;59(2):246-253. Not in File. doi:10.1002/pbc.23357 [doi]
- 117. Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ. Initial testing (stage 1) of the
polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;57(2):268-274. Not in File. doi:10.1002/pbc.22797 [doi]
- 118. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ. Initial testing (stage 1)
of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2010;54(2):307-310. Not in File. doi:10.1002/pbc.22188 [doi]
- 119. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ. Stage 1 testing and pharmacodynamic
evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;51(1):34-41. Not in File.
- 125. Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by
the pediatric preclinical testing program. Pediatr Blood Cancer.
2008;50(5):992-1000. Not in File.
- 137. Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing
(Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer.
2013;60(11):1860-1867. Not in File. doi:10.1002/pbc.24647 [doi]
- 149. Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, Lock R, Carol H, Keir S, Billups C, Kurmasheva R, Houghton P. Abstract C206: Pediatric
Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ). Molecular
Cancer Therapeutics. 2013;12(11 Supplement):C206-C206. Not in File.
- 153. Kolb EA, Gorlick R, Houghton PJ, Morton C, Maris JM, Courtright J, Carol H, Lock R, Friedman HS, Keir ST, M.H. K, Reynolds CP, Smith MA. Pediatric
Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor sorafenib. Proc Amer Assoc Cancer Res.
2009;50:3196-3196. Not in File.
- 154. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the
IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer.
2011;56(4):595-603. Not in File. doi:10.1002/pbc.22741 [doi]